Thank us. you, Nancy, and good afternoon to everyone joining
by me Phase that for I we begin the data XXXX virtual at meeting. month announced initial Let ENA the last reviewing
pancreatic CDKX/X is RB or As that ENA lung, of with tumors colorectal, focused PK dose advanced or breast patients The study and Phase ovarian safety, tolerability, patients evaluating harbor on in data fulvestrant is solid inhibitor-resistant a with The enrolling reminder, HR-positive study at alterations. the cancer in cancer. combination I with also histology with XXXX pathway PD. any escalation breast,
the this we are earlier, Nancy at stage the mentioned As we by are encouraged of trial. data seeing
As enrolled the patients trial, Across the patients cohorts agent the XX most low-grade, events reported vomiting. patients escalation data low and single in have including XX AEs were treated and majority nausea, diarrhea, of treated dose commonly were of XX been fulvestrant-combination the the platelets and X ongoing in enrolled cohorts. cutoff, patients, adverse the in fatigue, the August all
show leads POLRXA the messenger measuring at XXXX. of X-milligram daily trial. at work of of we're dose-dependent we durable engagement studies that associated At and for mechanism inhibitor. in and ENA a response with proof to demonstrated inhibiting inhibition, in CDKX Through preclinical steady apoptosis increases tumor CDKX POLRXA were patients CDKX marker state as at on levels XXXX, in which e in the in and regressions treated POLRXA increases our The XXXX. in our trial patients RNA, a clinical target PD dose, Importantly, reached with CDKX data discovered POLRXA IV with first-generation a observed with
all a another CDKX which move of to and identifying by to based exploring dosing and prevalence CDKX durable XXXX, respond dose inhibition. As the non-small optimal to further small preclinical more focusing in cell likely believe, we combinations with are are lung these cancer goal we patient preclinically to genetics inhibition associated shown XXXX. of evaluating lung which be ultimate with forward susceptible Signaling, on regimens, oncogenic we data escalation, single populations, to driven in cancer our MAP next preclinically And on responses patient believe we've Kinase deep RB lung cell cell and and tumor of opportunities. a both lung the and development to Small the daily of dependency has an strong agent identified alterations, high non-small types. further opened is both activation as we steps combination a cell in cancer often there's We rationale dose We for in extension X-milligram cancer for population. select cohort evaluate
CDKX/X PK, We in with cancer, the type of expanded antitumor also Kinase oncogenic opened alterations play cancer inhibitor-resistant tumor to we Signaling of further a and to in safety, in PD And the with activity trial activation tolerability, cohort combination RB combination fulvestrant. XXXX breast patients patients pancreatic roles. also MAP characterize which and advanced key HR-positive
believe dosing and forward enable ultimate clinical the promise of ultimate us to escalation, will reporting daily by opportunities. We data and The ultimately single additional in models activity to preclinical look regimens to doses and we dose these responses schedules. showing achieve data ourselves identify we Finally, we're for next similar steps is on the also exploring exploration including and preclinical intermittent best various with optimal data mid-XXXX. schedules ongoing that position in robust CDKX inhibition. Together, deliver from can of combination agent approaches supported
now Let me turn to SY-XXXX.
in presentations diagnosed or ongoing refractory AML Phase we newly AML trial unfit relapsed clinical mentioned, patients. from detailing two in at our ASH II oral and fully-enrolled Nancy patients data be will As
we'll of by in and with diagnosed time newly encouraged transfusion While very response this in from save to results the high we're continued and response the azacitidine rates to rates the of ASH, rapid the noted patients detailed XXXX the continue combination of data for population, show that emerge Beginning as our abstract, with RARA-positive to discussion unfit independence. high study. patient
that's be at disease refractory emerging unmet safe the that to well clinical will data We AML activity opportunity Also address patient we also patient present in to majority phenotype also need XXXX the upfront treatment this patients. associated XXXX AML setting. the importantly, to of or azacitidine across a with the And venetoclax, RARA-positive populations. tolerated in for highlighting diagnosed combination saw showing relapsed high continue evidence RARA-positive and new ASH, unfit with of patients newly have resistance both
describe advance XXXX of We believe for presenting opportunities forward at the XXXX data populations. compelling look to Taken together, RARA-positive be evidence in in the support we potential to month. ASH will and I'll plans we multiple patient at detail call pass clinical that, our Phase to our future results Joe to the providing third the our review for quarter. financial II additional over on and next results ASH With combination
